



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals

Citation for published version:

Thompson, KA, Cherry, CL, Bell, JE & McLean, CA 2011, 'Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals' *American Journal Of Pathology*, vol 179, no. 4, pp. 1623-9. DOI: 10.1016/j.ajpath.2011.06.039

Digital Object Identifier (DOI):

[10.1016/j.ajpath.2011.06.039](https://doi.org/10.1016/j.ajpath.2011.06.039)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

American Journal Of Pathology

Publisher Rights Statement:

© 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Short Communication

Brain Cell Reservoirs of Latent Virus in Presymptomatic HIV-Infected Individuals

Katherine A. Thompson,* Catherine L. Cherry,[†]
Jeanne E. Bell,[‡] and Catriona A. McLean*

From the Pathology Research Laboratory, Anatomical Pathology Unit and the Centre for Virology,[†] Burnet Institute, Infectious Diseases Unit, The Alfred Hospital, Department of Medicine, Monash University, Melbourne, Australia; and the Neuropathology Unit,[‡] University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom*

We detected HIV-1 DNA in pure populations of perivascular macrophages, parenchymal microglia, and astrocytes, isolated using laser microdissection from brain tissue of five untreated individuals who died in the presymptomatic stage of infection from non-HIV causes. HIV-1 DNA was detected in the three cell populations, most consistently in perivascular macrophages, without evidence of productive infection. The percentage of PCR reactions detecting HIV-1 DNA in perivascular macrophages correlated inversely with peripheral blood CD4 counts. These findings demonstrate that brain cell reservoirs of latent HIV-1 exist before pathological HIV encephalitis and suggest that perivascular macrophage trafficking of latent virus into the brain increases with immunosuppression. (Am J Pathol 2011, 179:1623–1629; DOI: 10.1016/j.ajpath.2011.06.039)

Establishing whether a specific cellular site of latent HIV-1 infection exists within the brain before the development of pathological HIV encephalitis (HIVE) is critical to understanding the nature of the central nervous system (CNS) HIV reservoir. The brain cell types or type within which virus is latent (DNA detection in the absence of detectable viral protein) has not been established. Studies have been hampered by the limited availability of autopsy brain tissue from individuals who have died before end-stage HIV disease and by techniques that lack both cell specificity and sensitivity for low copy viral DNA detection.

We studied a unique cohort of HIV-positive, presymptomatic individuals who died before pathological evidence of HIVE and used microdissection techniques to obtain pure

cell populations from specific brain regions. Genomic DNA extracted from astrocytes, perivascular macrophages, and parenchymal microglia were used as a template in a highly sensitive, triple-nested PCR to amplify and sequence a 119-bp fragment of the HIV-1 *gag* gene. These techniques achieved a specificity and sensitivity not previously possible and enabled us to detect latent HIV-1 in resident brain cells, suggesting that cellular viral reservoirs exist in the brain before onset of HIVE.

Materials and Methods

Brain Pathology

Autopsy brain tissue blocks were obtained from the Medical Research Council HIV Tissue Resource (Edinburgh) and were examined according to guidelines endorsed by the Alfred Hospital Human Ethics committee (HREC #81/07). Five individuals with untreated, established HIV-1 infection who died from HIV-unrelated causes were examined. They had no evidence of HIVE, nor of any other HIV-related neuropathology at autopsy. Similarly, there was no evidence of any AIDS-defining infection, malignancy, or neurological disease.¹ These individuals were therefore considered to be presymptomatic, with a spectrum of immunodeficiency. Brain tissue from two HIVE and two HIV-negative individuals were used as positive and negative controls, respectively. HIVE was diagnosed pathologically by productive infection of HIV-1 (as evidenced by p24 expression) of perivascular macrophages with or without giant cells with evident microglia activation and/or microglial nodules. Brains were routinely fixed, sectioned, and embedded. Using clean microtome blades, sections (5 μ m thick) from the occipital cortex were cut, placed onto charged glass slides, and air-dried overnight before immunohistochemical staining.

Supported by an Australia National Health and Medical Research Council Peter Doherty fellowship (415006 to K.A.T.).

Accepted for publication June 28, 2011.

Address reprint requests to Katherine Thompson, Ph.D., Anatomical Pathology Unit, The Alfred Hospital, 55 Commercial Rd., Melbourne, 3004 VIC, Australia. E-mail: katherine.thompson@monash.edu.

Table 1. Clinical Backgrounds, Immunohistochemical Detection, and PCR Detection of HIV-1 *gag* DNA in Brain Cell Populations of Study Subjects

Subject code no.	Sex	Age (years)	Cause of death	Hepatitis		CD4 T-cell count*	Clinical neurological status
				B	C		
HIV-positive, encephalitic							
75	M	29	Sepsis	+	-	0	HIVD
138	M	59	Sepsis	-	-	6	HIVD
Mean							
HIV-positive, presymptomatic							
245	M	35	Cirrhosis	+	+	18	No CI
205	M	34	OD	+	-	80	No CI
305	M	34	Cirrhosis	-	+	229	No CI
281	F	29	OD	+	-	260	ND
240	M	40	OD	+	+	496	No CI
Mean							
HIV-negative							
310	M	45	RTA	-	-	ND	No CI
170	M	60	Sepsis**	-	-	ND	No CI
Mean							

(table continues)

*Last recorded CD4 T-cell count.

†Detection of HIV-1 *gag* DNA from microdissected cell populations by triple-nested PCR. The number of positive (HIV-1 *gag* DNA detected) PCR reactions divided by the total number of triple-nested PCRs performed on each cell population (also expressed as a percentage).

‡Mean of 10 fields counted under a 40 \times objective.

§Total area stained (expressed as a percentage).

¶Increased activation or cell numbers compared with corresponding brain cell populations in the HIV-positive presymptomatic group and HIV-negative group ($P = 0.05$).

||Increased activation or cell numbers compared with corresponding brain cell populations in the HIV-negative group ($P = 0.05$).

**Immunosuppressed (lung transplant recipient).

Astro, astrocytes; CI, cognitive impairment; F, Female; HIVD, HIV-associated dementia; M, Male; Micro, parenchymal microglia; ND, no data; OD, alcohol or drug overdose; PVM, perivascular macrophage; RTA, road traffic accident.

Cell and HIV-1 Identification

Routine H&E staining was performed. A 1:50 dilution of a glial fibrillary acidic protein (GFAP) antibody (Zymed Laboratories, South San Francisco, CA) was used to detect astrocytes. A 1:200 dilution of a CD68 antibody (DakoCytomation, Glostrup, Denmark) was used to detect cells of macrophage lineage. Perivascular macrophages and parenchymal microglia were distinguishable by shape and location. A 1:40 dilution of p24 antibody (DakoCytomation) was used to detect HIV-1 protein. All antibodies were used with the avidin-biotin complex method and a diaminobenzidine hydrogen peroxide product as the colorimetric substrate. *In situ* proximity ligation assay (Duolink II; Olink Bioscience, Uppsala, Sweden) was also performed for single HIV-1 protein recognition using a 1:40 dilution of p24 antibody (DakoCytomation), according to the manufacturer's protocol. Tissue sections were assessed by a neuropathologist (C.A.M.) and with Image-Pro Plus 6.0 image analysis software (MediaCybernetics, Bethesda, MD) for immunopositive cells, as described previously.²

Laser Microdissection

Perivascular macrophages, parenchymal microglia, and astrocytes within the white matter from the occipital region of the cerebral cortex were identified as described above and were laser dissected (P.A.L.M. Microlaser Technologies, Oberkochen/Bernried, Germany) from uncovered IHC stained sections on slides and collected as

pure cell populations for subsequent analysis. The occipital region provided a representative view of the immune reaction to HIV-1 in the brain.² At least 200 cells spanning the entire tissue section were collected from each of the three cell populations, in duplicate from each individual.^{3,4} Neurons were microdissected from adjacent cortical regions to provide internal negative controls, as described previously.³ Genomic DNA was extracted using the Arcturus PicoPure DNA extraction kit (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol.

Amplification and DNA Sequence Analysis of HIV-1 GAG

HIV-1 *gag* sequences were amplified from genomic DNA prepared from laser dissected, captured cell populations. KAPA2G robust hot start DNA polymerase (Kapa Biosystems, Boston, MA) was used to generate a 119-nucleotide (nt) *gag* fragment in a highly sensitive triple-nested PCR strategy using 40 cycles per round, as described previously.^{3,5} Primers used were designed against a highly conserved *gag* region from the HIV-1 clade B consensus sequence. The nucleotide (nt) numbers represent their position relative to the HIV-1 NL4.3 strain: round 1: forward 5'-AGAACCAAGGGGAAGTGACA-3' nt 1476-1496; reverse 5'-TTGGACCAACAAGGTTTCTGT-3' nt 1761-1741. Round 2: forward 5'-CCCTTCAGGAACAAATAGGATG-3' nt 1514-1536; reverse 5'-GAAGCTTGCTCGGCTCTTAG-3' nt 1718-1699. Round 3: forward 5'-TCCACCTATCCCAGTAG-

Table 1. *Continued*

Detection of HIV-1 <i>gag</i> DNA [<i>n/N</i> (% detection rate) [†]]			Cell count [‡] (no.)			IHC staining [§] (%)	
PVM	Micro	Astro	PVM	Micro	Astro	PVM, Micro	Astro
3/11 (27)	1/11 (9)	2/18 (11)	7.40	29.80	9.80	0.143167	0.814018
4/12 (33)	1/12 (8)	4/24 (17)	7.00	24.80	9.20	0.118800	0.742597
30	9	14	7.20 [¶]	27.30 [¶]	9.50*	0.130984 [¶]	0.778308 [¶]
4/15 (27)	1/10 (10)	1/11 (9)	2.70	9.90	7.20	0.012492	0.593083
2/10 (20)	2/18 (11)	1/10 (10)	1.50	18.10	4.60	0.012518	0.262532
2/10 (20)	0/18 (0)	4/29 (14)	0.40	8.90	4.20	0.012617	0.116776
2/20 (10)	2/20 (10)	5/22 (23)	2.90	9.80	1.80	0.026765	0.257186
1/12 (8)	6/16 (38)	0/13 (0)	3.10	10.40	3.20	0.082078	0.410261
17	14	11	2.12	11.42 [¶]	4.2	0.029294 [¶]	0.327968 [¶]
0/10 (0)	0/10 (0)	0/11 (0)	0.70	4.70	3.10	0.002492	0.056377
0/10 (0)	0/10 (0)	0/11 (0)	0.40	3.20	2.20	0.004189	0.034862
0	0	0	0.55	3.95	2.65	0.003341	0.045620

GAGAA-3' nt 1548-1569; reverse 5'-AGGGTTCCTTTGGTC-CTTGT-3' nt 1666-1647.

The sensitivity of the triple-nested PCR was determined using a plasmid-containing HIV DNA of known concentration as a template in the triple-nested PCR.⁵ Cell populations were collected in duplicate, and the triple-nested PCR was performed on each cell population at least 10 times to determine the frequency of detection. Integrity of DNA was established by performing a similar highly sensitive PCR analysis of cellular GAPDH levels, as described previously.³ PCR products were sequenced at the Applied Genetic Diagnostics laboratory, Melbourne University (Parkville, Australia), and were aligned against the clade B consensus sequence using DNAMAN 6.0 software (Lynn, Pointe-Claire, QC, Canada).

Statistical Analysis

Quantitative data were analyzed using nonparametric tests (Mann-Whitney *U*-test, Spearman rank correlation) in the Stata 10.1 software package (StataCorp, College Station, TX).

Results

Clinical details are summarized in Table 1. Neuropathological analysis detected microglial and astrocytic reactivity in the absence of HIV-1 p24 protein in brain tissue from the five cases (Figure 1). Image analysis confirmed increased microglia and astrocyte activation within cases, compared with HIV-1 negative controls (*P* = 0.05).

Activation of all cell types within HIVE was increased, compared with the cases and HIV-1-negative groups (*P* = 0.05) (Table 1).

Triple-nested PCR was used to determine the presence of HIV-1 *gag* DNA within genomic DNA extracted from perivascular macrophages, parenchymal microglia, and astrocytes. The sensitivity of the triple-nested PCR was determined to be ≥ 1 copies of HIV-1 *gag* DNA per reaction. The *gag* region was successfully amplified from perivascular macrophages for all five cases (Table 1 and Figure 2A). The *gag* region was successfully amplified from astrocytes in four of the five cases (not from subject code no. 240), and from parenchymal microglial cells in four of the five cases (not from subject code no. 305). The *gag* region was successfully amplified in all cell populations in both HIVE individuals and was detected in a greater proportion of perivascular macrophages compared with presymptomatic individuals. HIV-1 *gag* DNA was not detected in cell populations from HIV-1-negative controls or cortical neurons from HIV-1-infected individuals. Sequence analysis confirmed HIV-1 *gag* DNA fragments were amplified from the cases specified. Mean percentage interpatient sequence variation in the *gag* gene is 5%, and the degree of sequence variation in *gag* correlates with the length of HIV-1 infection.⁶ Our sequence analysis in a short segment of the HIV-1 *gag* gene showed a mean variation from the clade B consensus sequence of 6% in the two HIV encephalitic individuals and 3% in the HIV presymptomatic cases, reflecting expected variation between patients. Resulting amino acid sequences were aligned against the HIV-1 *gag* consensus sequence (Figure 2C).




Figure 1. Representative photomicrographs of immunohistochemically stained sections of the white matter from the occipital region of the cerebral cortex. **A–C:** HIV-negative, subject code no. 310. **D–F:** HIV-positive presymptomatic, code no. 240. **G–I:** HIV-positive presymptomatic, code no. 245. **J–L:** HIV-positive encephalitic, code no. 138. **A, D, G,** and **J:** GFAP immunoreaction, showing baseline astrocyte numbers in controls and increased astrocyte reactivity in both HIV-positive presymptomatic and HIV-positive encephalitic cases. **B, E, H,** and **K:** CD68 immunoreaction, showing baseline microglia in controls with a minor increase in macrophage/microglial reactivity in HIV-positive presymptomatic cases, and prominent reactivity in HIV-positive encephalitic cases. **C, F, I,** and **L:** *In situ* proximity ligation assay for detection of individual p24 protein, showing no evidence of p24 protein (**C, F,** and **I**) or showing p24 positivity (**L**), indicating productive infection with HIV protein (arrows). Hematoxylin counterstain. Scale bars = 40 μ m.

The frequency with which HIV-1 *gag* DNA was detected by triple-nested PCR in the perivascular macrophages of HIV-1-positive individuals correlated inversely with the peripheral blood CD4 count (Spearman correlation, $\rho = -0.93$, $P = 0.003$) (Figure 2B).

Discussion

The optimal time to begin combination antiretroviral therapy for chronically infected individuals remains to be determined, although current guidelines recommend starting treatment when CD4 cell counts are less than 350 cells/mL.^{7–9} Preventing the development of HIVE requires

an understanding of how, where, and when the virus accesses the brain and whether a latent viral reservoir exists within the CNS, sequestered from systemic immune surveillance. If such a reservoir is present, current therapeutics may be unable to eliminate an established CNS reservoir, allowing later reactivation. Key research priorities for HIV-1 eradication include identifying anatomical and cellular reservoirs, to allow the development of targeted strategies that eliminate virus from these sites.¹⁰

PCR studies have confirmed low levels of HIV-1 DNA in homogenized brain samples of some presymptomatic subjects without evidence of productive HIV infection.¹¹




Figure 2. Analysis of HIV-1 *gag* DNA isolated from laser microdissected brain cell populations; astrocytes, perivascular macrophages (PVM), and parenchymal microglia (PM) from HIV-presymptomatic (PS) and HIV-encephalitic (HIVE) cases. **A:** Representative images of HIV-1 *gag* DNA PCR resulting in three rounds of PCR products (286, 205, and 119 bp). HIV-1 *gag* DNA was not consistently detected in PCR amplification from samples in which there were low levels of virus. Cell populations were therefore collected in duplicate (two collections of astrocytes per case), and the triple-nested PCR was performed on each cell population at least 10 times, to increase the frequency of detection. Not every PCR amplification from DNA of cell populations is illustrated (results of PCR amplifications of HIV-1 *gag* DNA from all cell populations are given in Table 1 and sequencing results are shown here in panel B). Lane A, negative PCR control (water as DNA template) carried through three rounds of PCR. Lane B, code no. 281 (PS), PVM. Lane C, code no. 305 (PS), PVM. Lane D, code no. 281, astrocytes. Lane E, code no. 305, astrocytes. Lane F, code no. 75 (HIVE), astrocytes. Lane G, code no. 75, PVM. Lane H, code no. 138 (HIVE), astrocytes. Lane I, code no. 138, PVM. Lane J, code no. 75, PM. Lane K, code no. 138, PM. Lane L, code no. 281, PM. Lane M, code no. 305, PM. Lane N, Lymph node of HIV-positive patient, positive PCR control (overamplification results in PCR product not running through the gel). **B:** Association between CD4 T-cell count and the frequency with which HIV-1 DNA was detected by triple-nested PCR in perivascular macrophages (PVM, expressed as a percentage) in the occipital cortex for each of the seven HIV-positive individuals. **C:** Amino acid sequence alignment of HIV-1 *gag* DNA from PCR products of laser microdissected brain cell populations. Sequences are aligned and numbered according to the HIV-1 *gag* consensus sequence. ast, astrocyte; mac, perivascular macrophages; mic, parenchymal microglia.

Nonetheless, there is still no conclusive evidence as to which brain cells are harboring virus before the onset of HIVE.¹² Our ability to detect HIV-1 DNA from specific brain cell types in a cohort of individuals who died from

HIV-unrelated causes during presymptomatic infection presented a unique opportunity to identify cellular viral reservoirs of the brain. Our detection of HIV-1 *gag* DNA in long-lived brain cells without evidence of productive in-

fection suggests that brain cell reservoirs of latent virus exist before HIVE onset. By the time of HIVE, both perivascular macrophages and parenchymal microglia demonstrate productive HIV-1 infection in the brain, but astrocytes, which have been shown to contribute to neuropathogenesis, are not productively infected.^{3,13,14}

Parenchymal microglia are a stable, long-lived CNS cell population that form a dense network throughout the brain. Their anatomical location and morphology is distinct from that of perivascular macrophages. Latently infected parenchymal microglia in presymptomatic HIV-1 infection may well represent a constant CNS viral reservoir. Circulating blood monocytes traffic into the perivascular space to become tissue perivascular macrophages and are constantly turned over via the systemic circulation.^{15–18} We previously examined brain cell-specific infection at multiple time points from acute to terminal infection in simian immunodeficiency virus (SIV) infected macaques. The study demonstrated that infected macrophages act as the Trojan horse within the brain perivascular space, with an initial increase in latent infection of perivascular macrophages and subsequent productive infection of perivascular macrophages and brain parenchymal cells concurrent with increasing plasma viral load and decreasing peripheral blood CD4 count.⁵ In our present study, we have similarly demonstrated increasing immunosuppression correlating with increasing latent HIV-1 infection of circulating perivascular macrophages before the onset of HIVE. Both studies suggest that perivascular macrophages may be pivotal in advancing HIV-1 brain infection at times of increasing immunosuppression and that maintaining CD4 cell levels may be crucial for controlling a critical entry point of HIV-1 from the systemic circulation into the brain. It is yet to be determined whether the onset of HIVE is due to reactivation of the microglial reservoir, influx of systemic HIV via infected macrophages, or both.

Our studies show microglial and astrocytic reactivity in the absence of HIV-1 p24 protein in brain tissue from presymptomatic individuals and that CD4 lymphocytic infiltration of the brain was negligible.² Given latent virus detected within brain cells before HIVE, this low-level activation of microglia and astrocytes may indicate a response to trafficking of HIV-1 into the brain and/or a change in the replication state of the latent infection.

CNS infiltration of activated monocytes/macrophages and microglial activation have been widely reported to be essential in the development of HIV-associated neurological disorders.^{12,19–22} A recent study showed that risk of HIV-associated neurological disorders is associated with nadir CD4 count.²³ Preventing CD4 decline by earlier initiation of combination antiretroviral therapy may reduce entry of HIV-1 infected perivascular macrophages from the systemic circulation into the brain and so reduce the likelihood of HIV-associated neurological disorders.

In conclusion, we provide evidence that brain cell reservoirs of latent HIV-1 exist before the onset of pathological HIVE and suggest that perivascular macrophages may be pivotal to brain disease progression at times of increasing immunosuppression. Therapies to prevent

CNS HIV disease progression may thus need to target perivascular macrophages, before immunosuppression.

Acknowledgments

We thank Frances Carnie and the MRC HIV Brain and Tissue Bank (Edinburgh, UK) for providing samples and clinical information analyzed in this study. We also thank the staff of Anatomical Pathology, Alfred Hospital, for assistance with processing tissue samples.

References

1. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep* 1992, 41(RR-17):1–19
2. McCrossan M, Marsden M, Carnie FW, Minnis S, Hansoti B, Anthony IC, Brettell RP, Bell JE, Simmonds P: An immune control model for viral replication in the CNS during presymptomatic HIV infection. *Brain* 2006, 129:503–516
3. Thompson KA, Churchill MJ, Gorry PR, Sterjovski J, Oelrichs RB, Wesselingh SL, McLean CA: Astrocyte specific viral strains in HIV dementia. *Ann Neurol* 2004, 56:873–877
4. Trillo-Pazos G, Diamanturos A, Risllove L, Menza T, Chao W, Belem P, Sadiq S, Morgello S, Sharer L, Volsky DJ: Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. *Brain Pathol* 2003, 13:144–154
5. Thompson KA, Varrone JJ, Jankovic-Karasoulos T, Wesselingh SL, McLean CA: Cell specific temporal infection of the central nervous system in a simian immunodeficiency virus model of human immunodeficiency virus encephalitis. *J Neurovirol* 2009, 15:300–311
6. Yoshimura FK, Diem K, Learn EH, Riddell S, Corey L: Intrapatient sequence variation of the gag gene of human immunodeficiency virus type 1 plasma virions. *J Virol* 1996, 70:8879–8887
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC, Department of Health and Human Services. January 10, 2011. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>, last accessed August 6, 2011
8. Hirsch MS: Initiating therapy: when to start, what to use. *J Infect Dis* 2008, 197 Suppl 3:S252–S260
9. Gatell JM: When and why to start antiretroviral therapy? *J Antimicrob Chemother* 2010, 65:383–385
10. Thomas C: Roadblocks in HIV research: five questions. *Nat Med* 2009, 15:855–859
11. Bell JE, Busuttill A, Ironside JW, Rebus S, Donaldson YK, Simmonds P, Peutherer JF: Human immunodeficiency virus and the brain: investigation of virus load and neuropathologic changes in pre-AIDS subjects. *J Infect Dis* 1993, 168:818–824
12. Anthony IC, Bell JE: The neuropathology of HIV/AIDS. *Int Rev Psychiatry* 2008, 20:15–24
13. Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ, Gorry PR: Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. *Ann Neurol* 2009, 66:253–258
14. Thompson KA, McArthur JC, Wesselingh SL: Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia. *Ann Neurol* 2001, 49:745–752
15. Kim WK, Alvarez X, Fisher J, Bronfin B, Westmoreland S, McLaurin J, Williams K: CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. *Am J Pathol* 2006, 168:822–834
16. Kim W-K, Corey S, Alvarez X, Williams K: Monocyte/macrophage traffic in HIV and SIV encephalitis. *J Leukoc Biol* 2003, 74:650–656
17. Bechmann I, Kwizdzinski E, Kovac AD, Simbürger E, Horvath T, Gimsa U, Dirnagl U, Priller J, Nitsch R: Turnover of rat brain perivascular cells. *Exp Neurol* 2001, 168:242–249

18. Williams KC, Corey S, Westmoreland SV, Pauley D, Knight H, deBakker C, Alvarez X, Lackner AA: Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. *J Exp Med* 2001, 193:905–916
19. González-Scarano F, Martín-García J: The neuropathogenesis of AIDS. *Nat Rev Immunol* 2005, 5:69–81
20. Bell JE: An update on the neuropathology of HIV in the HAART era. *Histopathology* 2004, 45:549–559
21. Gartner S: HIV infection and dementia. *Science* 2000, 287:602–604
22. Glass JD, Fedor H, Wesselingh SL, McArthur JC: Immunocytochemical analysis of HIV-gp41 and macrophages in HIV-associated dementia. *Ann Neurol* 1995, 38:755–762
23. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I; CHARTER Group: HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology* 2010, 75:2087–2096